title: Atenolol to treat intestinal ischemia and reperfusion in rats.
abstract: To study whether treatment with the beta-blocker atenolol (AT) attenuates intestinal dysfunction caused by ischemia (I) and reperfusion (R), rats were treated with AT (1.5 mg · kg(-1), intravenously) or saline solution (SS) prior to I (60 minutes), which was produced by occlusion of the superior mesenteric artery, and/or R (120 minutes). After I or I/R, 2-cm jejunal segments were mounted in an organ bath to study neurogenic contractions stimulated by electrical pulses or KCl using a digital recording system. Thin jejunal slices were stained with hematoxylin and eosin for optical microscopy analysis. Compared to the sham group, jejunal contractions were similar in the I + AT and the I/R + AT groups, but reduced in the I + SS and the I/R + SS groups. The jejunal enteric nerves were damaged in the I + SS and the I/R + SS groups, but not in the I + AT and the I/R + AT. These results suggest that AT may attenuate intestinal dysfunction caused by I and I/R.
authors.affiliation: Departments of Pharmacology, Biochemistry, Morphology, and Surgery, Federal University of São Paulo, São Paulo, Brazil.
authors.forename: V F
authors.initials: VF
authors.lastname: Campos
authors.forename: R
authors.initials: R
authors.lastname: Miranda-Ferreira
authors.forename: N S A
authors.initials: NS
authors.lastname: Taha
authors.forename: G D
authors.initials: GD
authors.lastname: Teixeira
authors.forename: W T I
authors.initials: WT
authors.lastname: Souza
authors.forename: C E F
authors.initials: CE
authors.lastname: Carmo
authors.forename: L A
authors.initials: LA
authors.lastname: Silva-Neto
authors.forename: I T
authors.initials: IT
authors.lastname: Gomes
authors.forename: H P
authors.initials: HP
authors.lastname: Monteiro
authors.forename: E F S
authors.initials: EF
authors.lastname: Montero
authors.forename: D J
authors.initials: DJ
authors.lastname: Fagundes
authors.forename: A
authors.initials: A
authors.lastname: Caricati-Neto
authors.forename: M O
authors.initials: MO
authors.lastname: Taha
mesh_terms: D058671:Adrenergic beta-1 Receptor Antagonists / Q000494:pharmacology*; D000818:Animals; D001262:Atenolol / Q000494:pharmacology*; D019610:Cytoprotection; D004195:Disease Models, Animal; D004558:Electric Stimulation; D017615:Enteric Nervous System / Q000187:drug effects / Q000503:physiopathology; D005765:Gastrointestinal Agents / Q000494:pharmacology*; D005769:Gastrointestinal Motility / Q000187:drug effects; D007583:Jejunum / Q000098:blood supply* / Q000187:drug effects* / Q000294:innervation / Q000473:pathology / Q000503:physiopathology; D008297:Male; D011189:Potassium Chloride / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*
chemical_list: D058671:Adrenergic beta-1 Receptor Antagonists; D005765:Gastrointestinal Agents; D001262:Atenolol; D011189:Potassium Chloride